Tuesday 6 November 2012
Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor currently in Phase I/II clinical development.
Rucaparib (AG 014699) is a PARP inhibitor being investigated as a potential anti-cancer agent.
Rucaparib inhibits "the contraction of isolated vascular smooth muscle, including that from the tumours of cancer patients. It also reduces the migration of some cancer and normal cells in culture."
It has undergone phase I clinical trials for patients with advanced solid tumours. It is in phase II clinical trials for metastatic breast and ovarian cancer with known BRCA1 or BRCA2 mutation.
It can be taken orally in tablet form.